|
2024
|
Invention
|
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage.
The present inv... |
|
2023
|
Invention
|
Linkers for site-specific antibody conjugation. Herein is reported a polypeptide-linker-nucleic a... |
|
|
Invention
|
Antisense oligomers targeting pcsk9.
The present invention relates to oligomeric compounds and c... |
|
|
Invention
|
Oligonucleotides targeting xbp1.
The invention relates to antisense oligonucleotides which alter... |
|
2022
|
Invention
|
Process for oligonucleotide purification. The present invention relates to a process for purifyin... |
|
|
Invention
|
Antisense oligonucleotides targeting alpha-synuclein and uses thereof. The present disclosure rel... |
|
|
Invention
|
Oligonucleotides comprising a phosphorodithioate internucleoside linkage.
The present invention ... |
|
2021
|
Invention
|
Oligonucleotides targeting xbp1. The invention relates to antisense oligonucleotides which alter ... |
|
|
Invention
|
Oligonucleotide formulation method.
The present invention relates to a method for determining th... |
|
|
Invention
|
Phosphonoacetate gapmer oligonucleotides.
The invention relates to a single-stranded antisense g... |
|
|
Invention
|
Novel phosphoramidites.
The invention relates to a compound of formula (II)
The invention rela... |
|
|
Invention
|
Antisense oligomers targeting pcsk9. The present invention relates to oligomeric compounds and co... |
|
|
Invention
|
Camk2d antisense oligonucleotides and uses thereof.
The present disclosure relates to antisense ... |
|
|
Invention
|
Guanosine analogues for use in therapeutics polynucleotides.
The present invention relates to a ... |
|
|
Invention
|
Guanosine analogues for use in therapeutic polynucleotides. The present invention relates to a po... |
|
|
Invention
|
Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides. The present in... |
|
|
Invention
|
In vitro toxicity screening assay.
The invention relates to methods for predicting the in vivo t... |
|
|
Invention
|
Microrna-134 biomarker.
The invention relates to the field of secondary markers for microRNA act... |
|
|
Invention
|
Oligonucleotides for splice modulation of camk2d. The present disclosure relates to oligonucleoti... |
|
2020
|
Invention
|
Pharmaceutical composition.
The invention provides pharmaceutical compositions comprising short ... |
|
|
Invention
|
Novel process for preparing rhenium chelated mag3 oligonucleotides.
The present invention relate... |
|
|
Invention
|
Novel process for preparing rhenium chelated mag3 oligonucleotides. The present invention relates... |
|
|
Invention
|
Novel process for preparing nucleotide p(v) monomers.
The present invention relates to an optimi... |
|
|
Invention
|
Novel process for preparing nucleotide p(v) monomers. The present invention relates to an optimiz... |
|
|
Invention
|
Stereodefined sub-motif optimisation methods.
The present invention relates to methods for ident... |
|
|
Invention
|
Angptl2 antisense oligonucleotides and uses thereof.
The present disclosure relates to antisense... |
|
|
Invention
|
Angptl2 antisense oligonucleotides and uses thereof. The present disclosure relates to antisense ... |
|
2019
|
Invention
|
Neoantigen engineering using splice modulating compounds.
The invention relates to the field of ... |
|
|
Invention
|
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage.
The present invention... |
|
|
Invention
|
Oligonucleotides for modulating myh7 expression.
The present invention relates to antisense olig... |
|
|
Invention
|
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing.
The inv... |
|
|
Invention
|
Massively parallel discovery methods for oligonucleotide therapeutics.
The invention relates to ... |
|
|
Invention
|
Antisense oligonucleotides targeting srebp1.
The present invention relates to antisense LNA olig... |
|
|
Invention
|
Oligonucleotides for modulating erc1 expression.
The present invention relates to antisense olig... |
|
|
Invention
|
Alpha-synuclein antisense oligonucleotides and uses thereof.
The present disclosure relates to a... |
|
|
Invention
|
Oligonucleotides for modulating gsk3b expression.
The present invention relates to antisense oli... |
|
|
Invention
|
Oligonucleotides for modulating pias4 expression.
The present invention relates to antisense oli... |
|
2018
|
Invention
|
Thiophosphoramidites. 5 and Nu are as defined in the description and in the claims. The compound ... |
|
|
Invention
|
Oligonucleotides for modulating fndc3b expression.
The present invention relates to antisense ol... |
|
|
Invention
|
Rapid unylinker cleavage. Methods for cleaving oligonucleotides from a solid support are describe... |
|
|
Invention
|
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotid... |
|
2017
|
Invention
|
Oligonucleotide synthesis.
The invention relates to a process for the manufacture of an oligonuc... |
|
|
G/S
|
Chemicals used in industry and science, including for
diagnostic purposes; chemicals for use in ... |
|
|
Invention
|
Stereodefining l-monomers. 8, when present, is cyanoethyl. The monomers have improved solubility ... |
|
|
G/S
|
Chemicals used in industry and science, including for diagnostic purposes; chemicals for use in t... |
|
2010
|
G/S
|
Chemicals used in industry and science, including for
diagnostic purposes; chemical reagents, no... |
